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The NTR domain of WFIKKN1 protein has been shown to have signifi-
cant affinity for the prodomain regions of promyostatin and latent myo-
statin but the biological significance of these interactions remained unclear.
In view of its role as a myostatin antagonist, we tested the assumption that
WFIKKN1 inhibits the release of myostatin from promyostatin and/or
latent myostatin. WFIKKN1 was found to have no effect on processing of
promyostatin by furin, the rate of cleavage of latent myostatin by BMP1,
however, was significantly enhanced in the presence of WFIKKN1 and
this enhancer activity was superstimulated by heparin. Unexpectedly,
WFIKKN1 was also cleaved by BMP1 and our studies have shown that
the KKN1 fragment generated by BMP1-cleavage of WFIKKN1 con-
tributes most significantly to the observed enhancer activity. Analysis of a
pro-TGF-b -based homology model of homodimeric latent myostatin
revealed that the BMP1-cleavage sites are buried and not readily accessible
to BMP1. In view of this observation, the most plausible explanation for
the BMP1-enhancer activity of the KKN1 fragment is that it shifts a con-
formational equilibrium of latent myostatin from the closed circular struc-
ture of the homodimer to a more open form, making the cleavage sites
more accessible to BMP1. On the other hand, the observation that the
enhancer activity of KKN1 is superstimulated in the presence of heparin is
explained by the fact KKN1, latent myostatin, and BMP1 have affinity for
heparin and these interactions with heparin increase the local concentra-
tions of the reactants thereby facilitating the action of BMP1.
Enzymes
Furin: EC 3.4.21.75; BMP1, bone morphogentic protein 1 or procollagen C-endopeptidase:
EC 3.4.24.19.
Introduction
Myostatin is a negative regulator of skeletal muscle
growth: mice lacking myostatin are characterized by a
significant increase in skeletal muscle mass [1]. Muta-
tions of the myostatin gene that interfere with the
formation of mature myostatin were also shown to
cause hypermuscularity in mice, cattle, dog, and
human [2–7]. In addition to its role in muscle develop-
ment, myostatin is also involved in regulation of
Abbreviations
Act RIIB, activin receptor IIB; BMP1, bone morphogenetic protein 1; KKN1, The C-terminal half of WFIKKN1 protein, containing its Kunitz 1,
Kunitz 2, and NTR domains; LM, latent myostatin; MSTN, myostatin gene; PCPE-1, procollagen C-proteinase enhancer-1; PMSF,
phenylmethylsulfonyl fluoride; TGF, transforming growth factor; WFI1, The N-terminal half of WFIKKN1 protein, containing its WAP,
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adipose tissue: in Mstn/ mice, adipose tissue size is
significantly reduced [8,9].
Myostatin is synthesized as an inactive precursor
protein, containing an N-terminal prodomain and a
C-terminal growth factor domain [10]. In promyo-
statin, two molecules are linked through a single disul-
fide bond present in the C-terminal growth factor
domain. Active myostatin (corresponding to the cova-
lently linked, homodimeric growth factor domain) is
released from promyostatin by proteolytic processing.
First, furin-type proprotein convertases cleave both
chains of the precursor at the boundary of the N-term-
inal prodomain and the C-terminal growth factor
domain. The importance of this step in the control of
myostatin activity is underlined by the observation
that the common K153R polymorphism of human
promyostatin that significantly increases the rate of its
proteolysis by furin is associated with obesity and
lower muscle strength [11]. Furin-cleavage of promyo-
statin, however, does not lead to the release of active
myostatin: the myostatin prodomains and the disul-
fide-bonded growth factor domains remain associated,
forming a noncovalent myostatin/prodomain complex
[12]. As the myostatin/prodomain complex does not
bind to the myostatin receptor, Act RIIB, the nonco-
valent myostatin/prodomain complex is referred to as
latent myostatin [12,13].
Active myostatin is released from latent myostatin
by proteases of the BMP1/Tolloid family that cleave
the prodomain of myostatin, thereby disrupting the
noncovalent myostatin/prodomain complex [14]. The
key importance of BMP1-mediated cleavage of latent
myostatin for the release of mature myostatin is
supported by the observation that mice carrying a
mutation that renders the myostatin prodomain
BMP1-resistant exhibit significant increase in muscle
mass [15].
Several myostatin antagonists exist that may control
the activity of mature myostatin. Lee and McPherron
were the first to show that follistatin, an activin antag-
onist, is also a potent inhibitor of myostatin [12]. Fur-
thermore, Hill et al. [16] have shown that myostatin is
bound to another inhibitory binding protein, the
FSTL3/FLRG protein (the product of the follistatin-
related gene, FLRG).
Two other follistatin-related proteins, the products
of the WFIKKN1 and WFIKKN2 genes were also
shown to have high affinity for myostatin [17,18]. Sig-
nificantly, WFIKKN1 and WFIKKN2 have higher
specificity for myostatin (and the closely related GDF-
11) than follistatin or FLST3/FLRG protein [19]. The
physiological significance of WFIKKN2 protein as a
key regulator of myostatin activity is supported by the
observation that delivery of WFIKKN2 gene into the
muscles of mice resulted in an approximately 30%
increase in muscle mass and that transgenic mice over-
expressing WFIKKN2 protein have larger muscles
compared to wild-type animals [20,21].
WFIKKN1 and WFIKKN2 are closely related pro-
teins that, in addition to a follistatin domain, contain
WAP domain, an immunoglobulin domain, two
Kunitz domains, and an NTR domain [22,23]. The
names of these proteins refer to the linear sequence of
their constituent WAP, follistatin, immunoglobulin,
Kunitz, Kunitz, and NTR domains [22,23]. In Fig. 1,
we show a schematic representation of the domain
architecture of the WFIKKN1 protein.
Our studies on these WFIKKN proteins have
revealed that their follistatin domains are primarily
responsible for the myostatin antagonist activity
[18,19,24], but relatively little is known about the func-
tion of the other domain types.
As WAP, Kunitz, and NTR domains have been
implicated in inhibition of various types of proteases,
we have hypothesized that the corresponding domains
of WFIKKN proteins might also function as protease
inhibitors [22–24]. Full-length WFIKKN proteins were
found to inhibit the proteolytic activity of bovine tryp-
sin but they had no effect on the peptidolytic activities
of bovine elastase, chymotrypsin, tissue-type plasmino-
gen activator, urokinase-type plasminogen activator,
furin, and BMP1 [24]. At the domain level, the trypsin
inhibitory activity of WFIKKN proteins was assigned
to their second Kunitz-type domain [25].
Interestingly, the NTR domain of WFIKKN1 (but
not of WFIKKN2) was found to have significant affin-
ity for myostatin prodomain [18,26]. This difference
between WFIKKN1 and WFIKKN2 is also reflected
in their interactions with promyostatin and latent myo-
statin; although WFIKKN1 has affinity for both
promyostatin and latent myostatin, WFIKKN2 had
no affinity for these proteins, suggesting that the
NTR/prodomain interaction mediates the interaction
of WFIKKN1 with promyostatin and latent myostatin
[18,26]. Detailed analysis of the WFIKKN1–prodomain
interaction revealed that WFIKKN1 binds the
C-terminal subdomain of myostatin prodomain, but
not the N-terminal subdomain that plays a critical role
in the interaction of the prodomain with mature myo-
statin [26]. It thus appears that myostatin prodomain
consists of two functionally distinct subdomains: the
N-terminal subdomain binds mature myostatin,
whereas the C-terminal subdomain binds WFIKKN1.
Very little is known about the biological significance
of the interaction of WFIKKN1 with myostatin
propeptide, promyostatin, and latent myostatin. In
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view of the role of WFIKKN1 and WFIKKN2 as
myostatin antagonists, we have speculated that the
interaction of WFIKKN1 with promyostatin and
latent myostatin might also serve as an antimyostatic
function, e.g., it may interfere with the release of
mature growth factor from promyostatin and/or latent
myostatin [24].
The goal of our present work was to investigate the
assumption that the interaction of WFIKKN1 with
the myostatin prodomain might inhibit furin-cleavage
of promyostatin and/or BMP1-cleavage of latent
myostatin.
Our studies have shown that WFIKKN1 has no
influence on the rate of furin-mediated cleavage of
promyostatin. The rate of cleavage of latent myo-
statin by BMP1, however, was significantly enhanced
in the presence of WFIKKN1 and this enhancer
activity was superstimulated by heparin. Unexpect-
edly, when latent myostatin was incubated with
BMP1 in the presence of WFIKKN1—concomitant
with the cleavage of latent myostatin—WFIKKN1
was also cleaved by BMP1 (Fig. 1). Our studies have
shown that the KKN1 fragment generated by
BMP1-cleavage of WFIKKN1 protein contributes
most significantly to the observed enhancer activity.
Cleavages of latent myostatin and WFIKKN1 pro-
tein by BMP1 are thus synergistic in the sense that
they promote the liberation of active myostatin from
latent myostatin.
Results and Discussion
Rate of cleavage of promyostatin by furin is not
affected by the promyostatin–WFIKKN1
interaction
Promyostatin was digested with furin in the presence
and absence of WFIKKN1 and WFIKKN2 proteins,
samples were withdrawn at various time points, and
their composition was analyzed by SDS/PAGE as
described in Materials and methods. As shown in
Fig. 2, neither WFIKKN1 nor WFIKKN2 had any
influence on the rate of decrease in the amount of
intact promyostatin and increase in the amount of
myostatin prodomain.
As in these experiments, we employed a molar
excess of WFIKKN1 over promyostatin, and the con-
centration of WFIKKN1 exceeded the Kd value of the
WFIKKN1/promyostatin interaction [26]. The lack of
WFIKKN1’s influence on the rate of furin-cleavage
suggests that the accessibility of the furin-cleavage site
of the myostatin precursor is not impaired in the
WFIKKN1/promyostatin complex. In other words,
the interaction of the NTR domain of WFIKKN1
with the prodomain of promyostatin does not shield
the furin-cleavage site of the precursor.
Rate of cleavage of latent myostatin by BMP1 is
significantly enhanced in the presence of
WFIKKN1 concomitant with cleavage of
WFIKKN1
Latent myostatin was digested with BMP1 in the
absence and presence of increasing concentrations
(0.5–4 lM) of WFIKKN1 protein and the samples
were analyzed by SDS/PAGE as described in Materi-
als and methods. As shown in Fig. 3, the rate of cleav-
age of myostatin prodomain by BMP1 was
significantly enhanced in the presence of WFIKKN1
(Fig. 3, panel B), and this rate enhancement was much
more pronounced when heparin was also included in
the reaction mixture (Fig. 3, panel C). Half-maximal
enhancer activity was achieved by ~ 0.5 lM of
WFIKKN1 in the absence of heparin and by ~ 1 lM
of WFIKKN1 in the presence of heparin.
Surprisingly, concomitant with the cleavage of myo-
statin prodomain, WFIKKN1 was also cleaved by
BMP1: as a result of cleavage of WFIKKN1 (Mr
~ 60 kDa) by BMP1 a diffuse band with an apparent
Mr of ~ 30 kDa appeared (Fig. 3, last two lanes in
panel A). Quantitative evaluation of the gels has
shown that the rate of cleavage of WFIKKN1 by
BMP1 is slightly, but significantly (P < 0.01, Student’s
t-test) enhanced in the presence of heparin.
These data indicate that the interaction of the NTR
domain of WFIKKN1 with the prodomain of latent
SP IGFSWAP KU NTRKU
Fig. 1. Domain architecture of WFIKKN1 protein. The name of this protein is an acronym that refers to its constituent WAP-, follistatin-,
immunoglobulin-, Kunitz-type protease inhibitory domains and NTR domain. The arrow indicates the position of the peptide bond that is
cleaved by BMP1.
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myostatin [18,26] increases the susceptibility of the
prodomain to BMP1-cleavage but it is not clear
whether the enhancer activity is mediated by the NTR
domain of full-length WFIKKN1 or of the WFIKKN
fragment(s) generated by BMP1-cleavage.
BMP1 cleaves the Arg287–Asp288 bond of
WFIKKN1
To characterize the BMP1-cleavage site of WFIKKN1,
we have incubated the protein (25 lg) with 2.5 lg
BMP1 in 100 lL of buffer containing 25 mM Tris/
HCl, 150 mM NaCl, 5 mM CaCl2, 1 lM ZnCl2, pH 7.5
at 37 °C for 6 h. Addition of BMP1 (2.5 lg) was
repeated and digestion was continued for a total of
16 h, then the C-terminal fragment carrying the
C-terminal His-tag of the WFIKKN1 protein [18] was
isolated by affinity chromatography on a 50 lL
Ni-NTA Sepharose column and by SDS/PAGE.
N-terminal sequence analysis of the ~ 30 kDa C-terminal
fragment yielded the amino acid sequence DAAPSI-
PAPAEXLPDV corresponding to residues 288–303 of
human WFIKKN1 indicating that the fragment was
generated by cleavage of the Arg287–Asp288 peptide
bond.
Residues Arg287–Asp288 are located between the
immunoglobulin and the first Kunitz domains of
WFIKKN1 (Fig. 1), thus cleavage of this peptide
bond by BMP1 generates WFI1 and KKN1 fragments
(calculated molecular masses: 28 845 and 29 181 Da,
respectively) corresponding to the N-terminal and a
C-terminal halves of the protein.
The observation that BMP1 cleaves the N-terminal
peptide bond of an aspartic residue of WFIKKN1 is
A
B C
Fig. 2. Furin-cleavage of promyostatin is not affected by the presence of WFIKKN1 or WFIKKN2. Promyostatin (500 nM) was incubated with
recombinant human furin (1 lgmL1) in 100 mM TRIS/HCl, 150 mM NaCl, 1 mM CaCl2, 100 mM phenylmethanesulphonylfluoride buffer, pH
8.0 at 28 °C for 0 min, 5 min, 15 min, 30 min, 1 h, 4 h (panel A), and 24 h (panel B) in the presence or absence of WFIKKN1 (1.5 lM) or
WFIKKN2 (1.5 lM) and nonreduced samples were analyzed by SDS/PAGE analysis; the gels were stained with Coomassie Brilliant Blue
G-250. At each time-point, lane 1 shows control samples lacking WFIKKN1 or WFIKKN2, lane 2 shows samples containing WFIKKN1, and
lane 3 shows samples containing WFIKKN2. Panel B also shows the results of control experiments, indicating that in the absence of furin,
no cleavage of promyostatin occurred. Panel C shows the quantitative evaluation of the data, indicating that neither WFIKKN1 nor WFIKKN2
had any influence on the rate of increase in the amount myostatin prodomain (the error bars indicate the standard error of the mean, n = 3).
Abbreviations: M, myostatin; PD, myostatin prodomain; PM, promyostatin; W1, WFIKKN1; W2, WFIKKN2.
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in harmony with the strict preference of BMP1 for
Asp residues in the P10 position. In the crystal struc-
ture of BMP1, there is an arginine (Arg176) in the S10
pocket; the presence of this basic residue in S10 fits
well with the known specificity of BMP1 for an aspar-
tic acid in the P10 position [27].
The importance of Asp288 of WFIKKN1 for its
susceptibility to BMP1-cleavage is supported by the
fact that its substitution by alanine rendered the pro-
tein resistant to cleavage by BMP1 (Fig. 4, last two
lanes in panel A). Aside from its Asp specificity at the
P10 position, BMP1 has little preference for residues at
positions adjoining the cleavage sites of protein sub-
strates (Table 1 and fig. 4 in [28]), suggesting that
accessibility of Xaa-Asp bonds plays an important role
in determining whether they serve as BMP1-cleavage
sites [28].
It is noteworthy in this respect that the BMP1-
cleavage site at Arg287–Asp288 of WFIKKN1 is in
a flexible low-complexity region (residues 274–298,
B C
97 kDa
66 kDa
45 kDa
30 kDa
20.1 kDa
W1
PD
M
PD_CT
PD_NT
LM + + + + + + + + + + + + + + +
BMP1 + + + + + + + + + + + + + + +
WFIKKN1 2 µM 0.1 µM 0.5 µM 1 µM 2 µM 4 µM 0.1 µM 0.5 µM 1 µM 2 µM 4 µM 2 µM 2 µM
heparin + + + + + + + +
A
Fig. 3. Rate of cleavage of latent myostatin by BMP1 is significantly enhanced in the presence of WFIKKN1 concomitant with cleavage of
WFIKKN1. Latent human myostatin (LM, 500 nM) was digested with 50 nM BMP1 in 25 mM HEPES buffer, pH 7.5 containing 150 mM NaCl,
5 mM CaCl2, 1 mM ZnCl2, and 1 mM furin inhibitor I at 37 °C for 16 h in the presence of increasing concentrations of WFIKKN1, in the
absence or presence of heparin (5 lgmL1). WFIKKN1 was also digested with BMP1 in the absence of latent myostatin in the presence or
absence heparin. Nonreduced samples were analyzed by SDS/PAGE analysis; the gels were stained with Coomassie Brilliant Blue G-250
(panel A). Panels B and C show the progress of BMP1 cleavage of prodomains as assessed from the decrease of the amount of uncleaved
prodomain (PD) and increase in the amount of C-terminal (PD_CT) and N-terminal (PD_NT) fragments resulting from BMP1-cleavage of the
prodomain; the error bars indicate the standard error of the mean, n = 3. Note that the amounts of PD_NT and PD_CT are significantly
higher in the presence of 0.5–4 lM WFIKKN1 than in its absence (panel B). Also note that in the presence of heparin and 2–4 lM WFIKKN1,
cleavage of myostatin prodomain (PD) is practically complete, whereas in the absence of WFIKKN1, the majority of PD is still intact (panel
C). Note that heparin also increases the rate of cleavage of WFIKKN1 (see last two lanes in panel A). Abbreviations: LM, latent myostatin;
M, myostatin; PD, myostatin prodomain; PD_CT, C-terminal fragment of myostatin prodomain; PD_NT, N-terminal fragment of myosatin
prodomain; W1, WFIKKN1.
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TARNAAGLLRADFPLSVVQREPARDAAPSIPAPAE)
that connects the immunoglobulin and the first Kunitz
domain of WFIKKN1. It is plausible to assume that
the flexibility of this disordered linker region plays a
key role in the susceptibility of this peptide bond to
BMP1-cleavage. Although the low-resolution solution
structure of WFIKKN1 [29] tells us very little about
the position of the various regions in the globular-like
structure of this multidomain protein, our data suggest
that the linker region connecting the N-terminal and
C-terminal halves of WFIKKN1 protein is exposed
and accessible for BMP1.
Rate of cleavage of latent myostatin by BMP1 is
not enhanced by the D288A mutant WFIKKN1 in
the absence of heparin
To decide whether full-length WFIKKN1 has rate-
enhancing activity, we substituted the Asp288 residue
with alanine to render the protein resistant to BMP1-
cleavage. As shown in Fig. 4 (panel B), when latent
myostatin was digested with BMP1 in the absence of
heparin, the rate of cleavage of myostatin prodomain
was practically unaffected by increasing concentrations
(0.5–4 lM) of D288A mutant WFIKKN1 protein,
B C
66 kDa
45 kDa
30 kDa
20.1 kDa
14.4 kDa
W1_D288A
PD
PD_NT
PD_CT
M
A LM + + + + + + + + + + + +
W1_D288A 0.5 µM 1 µM 2 µM 4 µM 0.5 µM 1 µM 2 µM 4 µM 2 µM 2 µM 2 µM
heparin + + + + + + +
BMP1 + + + + + + + + + + + +
Fig. 4. Rate of cleavage of latent myostatin by BMP1 is not enhanced by the D288A mutant WFIKKN1 in the absence of heparin. Latent
human myostatin (LM, 500 nM) was digested with 50 nM BMP1 in 25 mM HEPES buffer, pH 7.5 containing 150 mM NaCl, 5 mM CaCl2,
1 mM ZnCl2, and 1 mM furin inhibitor I at 37 °C for 16 h in the presence of increasing concentrations of the D288A mutant WFIKKN1, in the
absence or presence of heparin (5 lgmL1). Nonreduced samples were analyzed by SDS/PAGE analysis; the gels were stained with
Coomassie Brilliant Blue G-250 (panel A). Panels B and C show the progress of BMP1 cleavage of prodomains as assessed from the
decrease of the amount of uncleaved prodomain (PD) and increase in the amount of C-terminal (PD_CT) and N-terminal (PD_NT) fragments
resulting from BMP1-cleavage of the prodomain; the error bars indicate the standard error of the mean, n = 3. Note that in the absence of
heparin, the D288A mutant WFIKKN1 had little effect on the cleavage of latent myostatin (panel B), whereas in the presence of heparin, the
D288A mutant WFIKKN1 enhanced the cleavage of myostatin prodomain (panel C). Abbreviations: LM, latent myostatin; M, myostatin; PD,
myostatin prodomain; PD_CT, C-terminal fragment of myostatin prodomain; PD_NT, N-terminal fragment of myosatin prodomain;
W1_D288A, D288A mutant WFIKKN1.
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suggesting that the marked rate enhancement observed
in the case of the wild-type WFIKKN1 protein in the
absence of heparin (see Fig. 3, panel B) is caused by
the BMP1-cleavage product KKN1 and not the full-
length protein. In harmony with this conclusion, when
latent myostatin was digested with BMP1 in the
absence of heparin, recombinant KKN1 protein (0.5–
4 lM) significantly enhanced the rate of cleavage of
myostatin prodomain (Fig. 5, panel B). The efficiency
of KKN1 is illustrated by the fact that maximal
enhancer activity was achieved even by 0.5 lM KKN1,
the lowest concentration of KKN1 tested.
The most plausible explanation for the observation
that WFIKKN1 is less active as an enhancer than
the KKN1 fragment is that in the compact globular-
like structure of WFIKKN1 [29], interdomain interac-
tions render the NTR domain less accessible for
interaction with the myostatin prodomain. According
Table 1. Comparison of the BMP1-cleavage site of WFIKKN with those of known substrates of BMP1.
Substrate P4 P3 P2 P1 P10 P20 P30 P40
WFIKKN1 Glu Pro Ala Arg Asp Ala Ala Pro
Alpha-2-macroglobulin Phe Tyr Glu Ser Asp Val Met Gly
Apolipoprotein A-I Phe Trp Gln Gln Asp Glu Pro Pro
Heparan sulfate proteoglycan Ser Gly Gly Asn Asp Ala Pro Gly
Biglycan Leu Met Met Asn Asp Glu Glu Ala
Chordin precursor Arg Ser Tyr Ser Asp Arg Gly Glu
Chordin precursor Pro Met Gln Ala Asp Gly Pro Arg
Collagen alpha 1(I) precursor Tyr Tyr Arg Ala Asp Asp Ala Asn
Collagen alpha 1(II) precursor Tyr Met Arg Ala Asp Glu Ala Ala
Collagen alpha 1(VII) precursor Ser Tyr Ala Ala Asp Thr Ala Gly
Collagen alpha 2(I) precursor Phe Tyr Arg Ala Asp Gln Pro Arg
Collagen alpha-1(I) chain Tyr Tyr Arg Ala Asp Asp Ala Asn
Collagen alpha-1(II) chain Tyr Met Arg Ala Asp Gln Ala Ala
Collagen alpha-1(III) chain Pro Tyr Tyr Gly Asp Glu Pro Met
Collagen alpha-1(V) chain Thr Pro Gln Ser Gln Asp Pro Asn
Collagen alpha-1(V) chain Gln Leu Leu Asp Asp Gly Asn Gly
Collagen alpha-1(XI) chain Ala Ala Gln Ala Gln Glu Pro Gln
Collagen alpha-2(V) chain Glu Phe Thr Glu Asp Gln Ala Ala
Collagen alpha-2(XI) chain Arg Pro Gln Asn Gln Gln Pro His
Collagen alpha-3(V) chain Ser Phe Gln Gln Ala Gln Ala Gln
Decorin precursor Phe Met Leu Glu Asp Glu Ala Ser
Dentin matrix acidic phosphoprotein 1 Gly Met Gln Ser Asp Asp Pro Glu
DSPP600 Ser Met Gln Gly Asp Asp Pro Asn
gldn gliomedin Val Ile Pro Asn Asp Asp Thr Leu
Growth/differentiation factor 11 precursor Asp Phe Gln Gly Asp Ala Leu Gln
Growth/differentiation factor 8 precursor Asp Val Gln Arg Asp Asp Ser Ser
Insulin-like growth factor-binding protein Glu Ser Gln Ser Thr Asp Thr Gln
Insulin-like growth factor-binding protein 3 Tyr Glu Ser Gln Ser Thr Asp Thr
Laminin subunit gamma-2 Cys Tyr Ser Gly Asp Glu Asn Pro
Latent-transforming growth factor beta-binding protein 1 Ile Pro Ser Leu Asp Gln Glu Lys
Latent-transforming growth factor beta-binding protein 1 Tyr Phe Ile Gln Asp Arg Phe Leu
Lysyl oxidase homolog 3 Leu Ile Cys Gly Asp Asp Trp Gly
Lysyl oxidase-like 1 Val Ala Val Gly Asp Ser Thr Gly
Lysyl oxidase-like 1 Val Arg Ser Ser Asp Ala Pro Pro
Osteoglycin Gln Leu Gln Lys Asp Glu Val Ile
Probiglycan Phe Met Met Asn Asp Glu Glu Ala
Prolactin Leu Gln Met Ala Asp Glu Glu Ser
Prolysyl oxidase Arg Met Val Gly Asp Asp Pro Tyr
Prolysyl oxidase Gly Met Val Gly Asp Asp Pro Tyr
Prolysyl oxidase-like 1 Val Ala Val Gly Asp Ser Thr Gly
Somatotropin Asn Ser His Asn Asp Asp Ala Leu
Information on known peptide substrates of BMP1 (peptidase M12.005: procollagen C-peptidase) was compiled from the MEROPS data-
base; http://merops.sanger.ac.uk/cgi-bin/substrates?id=M12.005. Residues identical with those in the P4-P40 positions of WFIKKN1’s cleav-
age site are highlighted in bold.
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to this explanation, cleavage of WFIKKN1 by BMP1
liberates the KKN1 fragment from these interactions,
thereby increasing the accessibility of the NTR
domain and favoring its interaction with myostatin
prodomain.
It should be noted, however, that in the presence of
heparin, the D288A mutant WFIKKN1 protein also
has detectable enhancer activity (Fig. 4, panel C). Sim-
ilarly, the enhancer activity of KKN1 was more pro-
nounced when heparin was included in the reaction
mixture (compare panels B and C of Fig. 5).
Molecular basis of the enhancer activity of KKN1
on BMP1 activation of latent myostatin
To get an insight into the molecular basis of the
enhancer activity of KKN1 on BMP1-cleavage of
latent myostatin we have analyzed the structural char-
acteristics of the BMP1-cleavage sites of homodimeric
latent myostatin [11].
In the homology model of homodimeric latent myo-
statin (based on the crystal structure of homodimeric
pro-TGF-b1 [30]), the two monomers form a disk-like
B C
W1_KKN
PD
PD_N
PD_C
M
LM + + + + + + + + + + + +
W1_KKN 2 µM 0.5 µM 1 µM 2 µM 4 µM 2µM 0.5 µM 1 µM 2 µM 4 µM
heparin + + + + + +
BMP1 + + + + + + + + + +
66 kDa
45 kDa
30 kDa
20.1 kDa
14.4 kDa
A
Fig. 5. Rate of cleavage of latent myostatin by BMP1 is significantly enhanced by KKN1. Latent human myostatin (LM, 500 nM) was
digested with 50 nM BMP1 in 25 mM HEPES buffer, pH 7.5 containing 150 mM NaCl, 5 mM CaCl2, 1 mM ZnCl2, and 1 mM furin inhibitor I at
37 °C for 16 h in the presence of increasing concentrations of KKN1, in the absence or presence of heparin (5 lgmL1). Nonreduced
samples were analyzed by SDS/PAGE analysis; the gels were stained with Coomassie Brilliant Blue G-250 (panel A). Panels B and C show
the progress of BMP1 cleavage of prodomains as assessed from the decrease of the amount of uncleaved prodomain (PD) and increase in
the amount of C-terminal (PD_CT) and N-terminal (PD_NT) fragments resulting from BMP1-cleavage of the prodomain; the error bars
indicate the standard error of the mean, n = 3. Note that KKN1 enhanced the cleavage of latent myostatin both in the absence (panel B)
and presence of heparin (panel C). Abbreviations: LM, latent myostatin; M, myostatin; PD, myostatin prodomain; PD_CT, C-terminal
fragment of myostatin prodomain; PD_NT, N-terminal fragment of myosatin prodomain; W1_KKN, the KKN fragment of WFIKKN1.
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circular structure (Fig. 6). N-terminal parts of the two
prodomains, consisting of the a1 and a2 helices, pro-
vide the ‘straitjacket’ that encircles and shields each
growth factor monomer of the homodimer, whereas
the C-terminal parts of the two prodomains provide
the ‘arm domains’ that connect the two prodomains in
the homodimeric precursor. The ‘arm domains’ consist
of three distinct structural regions. A four-stranded
b-sheet (consisting of b1, b3, b6, and b10 strands and
buried by the a2, a3, and a4 helices) is in close prox-
imity of the growth factor monomer of the same
polypeptide chain, whereas a four-stranded b-sheet
(consisting of b2, b4, b5, and b7 strands) and
b-strands b8 and b9 extend to link the two arm
domains of the homodimeric precursor in a ‘bowtie’.
The loops containing the BMP1-cleavage sites of
latent myostatin are buried in the center of the disk-like
homodimer (Fig. 6), suggesting that they are not read-
ily accessible to cleavage by BMP1. The most plausible
explanation for the enhancer activity of KKN1 is
that binding of the NTR domain of KKN1 to the
C-terminal subdomains of myostatin prodomains
[18,26] loosens the ‘bowtie’, shifting the conformational
equilibrium from the circular structure toward a more
open form of latent myostatin making the BMP1-
cleavage sites more accessible to the enzyme.
Heparin-dependence of the activity of WFIKKN1
proteins as enhancers of BMP1-mediated
activation of latent myostatin
The heparin-dependence of the BMP1-enhancer activity
of WFIKKN1 (Fig. 3), D288A mutant WFIKKN1
(Fig. 4) and KKN1 (Fig. 5), is reminiscent of the
heparin-dependence of the BMP1-enhancer activity of
procollagen C-proteinase enhancer-1 protein (PCPE-1).
According to the model proposed by Bekhouche et al.
[31], the enhancer PCPE-1 binds to the substrate procol-
lagen III C-propeptides with high affinity and this
PCPE-1/procollagen complex binds to heparin-like gly-
cosaminoglycans via the NTR domain of PCPE-1 as well
as via procollagen III. As BMP1 also interacts with hep-
arin, these interactions increase the local concentrations
of the reactants facilitating the action of BMP1 [31].
We assume that an analogous model might explain
the heparin-dependence of the BMP1-enhancer activity
of WFIKKN1_D288A and KKN1 proteins, with latent
myostatin as substrate. A key aspect of this model is
that BMP1, latent myostatin, and WFIKKN1 proteins
are all bound to heparin and the increased local concen-
tration of the reactants facilitates the action of BMP1
on latent myostatin. It is well established that latent
myostatin [12] and BMP1 [32] have affinity for heparin,
Fig. 6. The BMP1-cleavage sites are buried in the center of the homodimer of latent myostatin. In the homology model of homodimeric
latent myostatin, the two monomers form a disk-like circular structure. N-terminal parts of the two prodomains (pale yellow – light gray)
provide the ‘straitjacket’ that encircles and shields each growth factor monomer of the homodimer (light blue – yellow), whereas the C-
terminal parts of the two prodomains (green – pink) provide the ‘arm domains’ that connect the two prodomains in the homodimeric
precursor in a ‘bowtie’. The loops containing the BMP1-cleavage sites of latent myostatin are buried in the center of the disk-like
homodimer, suggesting that they are not readily accessible to cleavage by BMP1. Our data suggest that binding of the NTR domain of
KKN1 to the C-terminal subdomains of myostatin prodomains loosens the ‘bowtie’, shifting the conformational equilibrium from the circular
structure to a more open form of latent myostatin making the BMP1 cleavage sites more accessible to the enzyme. The black arrows
indicate the position of the BMP1 cleavage sites between residues Arg98–Asp99. The positions of Arg98 and Asp99 are highlighted in red.
The figure in the right-hand panel was generated by 90° clockwise rotation of the homodimer around the y-axis.
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and in the present work, we have found evidence that
WFIKKN1 proteins also have significant affinity for
heparin. As shown in Fig. 7, both WFIKKN1 and
KKN1 have affinity for immobilized heparin. Interest-
ingly, KKN1 has higher affinity for heparin than the
full-length protein, suggesting that intramolecular inter-
actions of the compact globular WFIKKN1 protein
may partially bury the heparin-binding site. In view of
these findings, it seems likely that BMP1-cleavage of
WFIKKN1 favors the formation of the enhancer com-
plex, not only by increasing the accessibility of the NTR
domain for the myostatin prodomain but also by
increasing the heparin affinity of the enhancer.
In summary, in the present work we have shown
that WFIKKN1 is cleaved by BMP1 generating the
C-terminal KKN1 fragment that is a potent heparin-
dependent enhancer of BMP1-activation of latent
myostatin. BMP1-cleavage of WFIKKN1 protein and
latent myostatin are thus synergistic in the sense that
they promote the liberation of active myostatin from
latent myostatin complex.
Materials and methods
Reagents, enzymes, PCR primers, proteins,
bacterial strains
Mutagenesis primers were from Integrated DNA Technolo-
gies (Coralville, IA, USA). The mutagenesis reaction was
performed with Quickchange mutagenesis kit (Agilent Tech-
nologies, Inc. Santa Clara, CA USA). DNA was purified
with Nucleospin Extract DNA purification kit (Macherey-
Nagel, Duren, Germany). Escherichia coli JM109 was used
for DNA propagation during DNA manipulation steps, and
E. coli BL21(DE3) strain was used for protein expression.
Recombinant human promyostatin, human WFIKKN1,
and human WFIKKN2 were produced as described previ-
ously [18,19,26].
Recombinant furin, recombinant BMP1, (R&D Systems,
Minneapolis, MN, USA), furin inhibitor I (Merck Milli-
pore, Darmstadt, Germany), and heparin (Sigma-Aldrich,
St Louis, MO, USA) were commercial products. HiTrap
Heparin HP columns were obtained from GE Healthcare
Life Sciences (Budapest, Hungary).
FUGENE HD transfection reagent was purchased from
Promega (Madison, WI, USA). The culture media and fetal
bovine serum used for Drosophila S2 cell maintenance,
selection, and protein expression were from Invitrogen/
ThermoFisher Scientific (Waltham, MA, USA).
Production of the D288A mutant of human
WFIKKN1 in Drosophila melanogaster S2 cells
Mutagenesis was performed with QuikChange Site-Directed
Mutagenesis method with the 50CGAGAGCCGGCCAG
GGCCGCAGCCCCCAGCATCC30 sense and 50GGATG
CTGGGGGCTGCGGCCCTGGCCGGCTCTCG 30anti-
sense primers. The Drosophila expression vector pMT/BiP/
V5/His A containing the cDNA of human WFIKKN1 pro-
tein [18] was the template in the mutagenesis reaction. The
mutagenesis introduced an A to C change at position 863
of the human WFIKKN1 cDNA causing the D288A muta-
tion in the protein. The presence of the mutation was con-
firmed by DNA sequencing and the plasmid pMT/BiP/
WFIKKN1_D288A was used to produce stable transfected
Drosophila melanogaster S2 cells.
Drosophila melanogaster S2 cells (Drosophila Genomics
Resource Center, Indiana University, Bloomington, IN,
USA) were transformed in Schneider Drosophila Medium
containing 10% heat inactivated fetal bovine serum. The
expression plasmid pMT/BiP/WFIKKN1_D288A and pCo-
Hygro selection vector were mixed in a 19 : 1 ratio and
5 lg of the mixture was dissolved in 250 lL OPTIMEM
medium then 15 lL FUGENE HD transfection reagent was
added. Complex formation was allowed for 10 min then the
plasmid solution was added to 19 106 D. melanogaster S2
cells in 5 mL medium. About 24 h later, the media contain-
ing the transfection mixture was removed and the cells were
suspended in 5 mL of fresh Schneider Drosophila Medium
supplemented with 10% fetal bovine serum. Selection of
stable transfectants was initiated 96 h post transfection by
the addition of 300 lgmL1 hygromycin B to the culture
medium. The cells were grown for 72 h and the medium
was replaced by 5 mL of medium containing 70% of fresh
L
Fig. 7. The WFIKKN1 and KKN1 proteins have affinity for heparin.
About 1 mL aliquots of WFIKKN1 (5 lM) or KKN1 (5 lM) dissolved
in 50 mM Tris/HCl, 150 mM NaCl buffer, pH 7.5 were applied on
1 mL Hitrap Heparin Sepharose columns. The columns were
washed with 5 mL of buffer containing 50 mM Tris/HCl, 150 mM
NaCl, pH 7.5 and the proteins were eluted with a 10 mL gradient
of buffer A (50 mM Tris/HCl, 150 mM NaCl, pH 7.5) and buffer B
(50 mM Tris/HCl, 1.5 M NaCl, pH 7.4). Note that isolated KKN1 has
higher affinity for heparin than full-length WFIKKN1.
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Schneider Drosophila Medium and 30% of conditioned
medium collected from growing S2 cells and 300 lgmL1
hygromycin B was added. These steps were repeated every
third day and stably transformed polyclonal lines were
established after 5 weeks of selection.
Expression and purification of recombinant proteins
secreted by S2 cells was performed essentially as described
previously [18]. Stable transfectants were grown in Express
five serum-free insect medium to a cell density of 2–3 9 106
per mL, and protein expression was induced by adding
CuSO4 at 300 lM final concentration. After 1 week of induc-
tion, the culture was centrifuged and the medium was dia-
lyzed against 50 mM Tris/HCl buffer, pH 7.5, and applied
onto a Ni-NTA Sepharose column. The column was washed
with 10 column volumes of 20 mM Tris/HCl buffer, pH 7.9,
containing 500 mM NaCl and 5 mM imidazole then with 5
column volumes of 20 mM Tris/HCl buffer, pH 7.9, contain-
ing 500 mM NaCl and 30 mM imidazole, and the bound
protein was eluted with 20 mM Tris/HCl buffer, pH 7.9
containing 300 mM imidazole. The eluted protein was con-
centrated on Amicon Ultra-15 centrifugal filter devices and
chromatographed on a Superdex 300 column equilibrated
with 100 mM ammonium bicarbonate buffer, pH 8.0.
Production of the KKN1 fragment of WFIKKN1
protein in Drosophila melanogaster
The cDNA coding for fragments of WFIKKN1 protein were
amplified with Phusion high fidelity polymerase (New Eng-
land Biolabs, Ipswich, MA, USA) using the plasmid contain-
ing the full-length WFIKKN1 cDNA as template. The
cDNA of the fragment containing the two Kunitz domains
and the NTR domain (KKN1) was amplified with 50GG
AAGATCTGACGCAGCCCCCAGCATCCCA30 sense and
50GGAACCGGTGTCCTGGAAGCGGTTGAGCAGC30
antisense primers. The amplimers were digested with BglII
and AgeI enzymes and ligated into pMT/BiP/V5/HisA
expression plasmid digested with the same enzymes. Droso-
phila melanogaster S2 cells were transfected with the plasmid
pMT/BiP/KKN1 using the protocol described in section 4.2
and KKN1 protein was purified from the media as described
above.
Proteolytic digestion of promyostatin with furin
in the presence and absence of WFIKKN proteins
To monitor the influence of WFIKKN1 (1.5 lM) and
WFIKKN2 (1.5 lM) on furin-mediated cleavage of
promyostatin, human promyostatin (0.5 lM) was digested
with human furin (1 lgmL1) in 100 mM Tris/HCl,
150 mM NaCl, 1 mM CaCl2, 100 lM PMSF buffer, pH 8.0
at 28 °C. Aliquots were removed at various time points (0,
5, 15, 30 min, 1, 4, 24 h) and the composition of the sam-
ples was analyzed by SDS/PAGE.
Proteolytic digestion of latent myostatin with
human BMP1 in the presence and absence of
WFIKKN1 protein
Latent myostatin was produced by digesting promyosatin
(1 lM) with 3.5 lgmL1 furin in 100 mM Tris/HCl,
150 mM NaCl, 1 mM CaCl2, 100 lM PMSF buffer, pH 8.0
at 28 °C for 24 h. The digestion was arrested with 1 lM
furin inhibitor I; samples were stored at 20 °C.
To monitor the influence of WFIKKN1 protein (0.5,
1, 2, 4 lM) on BMP1-cleavage of latent myostatin by
SDS/PAGE, latent myostatin (0.5 lM) was digested with
BMP1 (50 nM) in 25 mM HEPES buffer, pH 7.5 contain-
ing 150 mM NaCl, 5 mM CaCl2, 1 lM ZnCl2, and 1 lM
furin inhibitor I at 37 °C for 16 h and the composition
of the samples was analyzed by SDS/PAGE. The experi-
ments were also performed in the presence of 5 lgmL1
heparin.
Protein analyses
The concentrations of the recombinant proteins were
determined using the following extinction coefficients:
promyostatin monomer, 55 640 M1cm1; WFIKKN1,
64 440 M1cm1; WFIKKN2, 57 470 M1cm1; KKN1,
32 065 M1cm1; the extinction coefficients were calculated
with the online protein analysis tool PROTPARAM.
(http://web.expasy.org/protparam/).
The composition of protein samples was analyzed by
SDS/PAGE under both reducing and nonreducing condi-
tions; unless otherwise indicated, the gels were stained with
Coomassie Brilliant Blue G-250. For quantitative evalua-
tion of protein compositions, the stained gels were scanned
with the ChemiImager 5500 gel documentation instrument
(Alpha Innotech, San Leandro, CA, USA) and the intensi-
ties of the protein bands were quantified with GELQUANT.-
NET software of BiochemLabSolutions (University of
California, San Francisco UCSF). In the case of each elec-
tropherogram, quantitative evaluation of protein composi-
tion was repeated six times.
To compare the rates of furin-mediated cleavage of
promyostatin in the presence and absence of WFIKKN
proteins, we monitored the changes in the band intensity of
myostatin prodomain formed as a result of furin-cleavage.
The rates of BMP1-mediated cleavage of latent myostatin
in the presence and absence of WFIKKN proteins were
compared in a similar way except that in this case we moni-
tored the changes in the band intensities of uncleaved myo-
statin prodomain as well as the two fragments generated by
BMP1-cleavage of the prodomain. All experiments were
performed in triplicate.
N-terminal sequencing of proteins was performed on an
Applied Biosystems 471A protein sequencer with an online
ABI 120A phenylthiohydantoin (PTH) analyzer.
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Hitrap Heparin Sepharose chromatography
One milliliter aliquots of WFIKKN1 (5 lM) or KKN1
(5 lM) in 50 mM Tris/HCl, 150 mM NaCl buffer, pH 7.5
were applied on 1 mL Hitrap Heparin Sepharose columns.
The columns were washed with 5 mL of buffer containing
50 mM Tris/HCl, 150 mM NaCl, pH 7.5, and the proteins
were eluted with a 10 mL gradient of buffer A (50 mM
Tris/HCl, 150 mM NaCl, pH 7.5) and buffer B (50 mM
Tris/HCl, 1.5 M NaCl, pH 7.4).
Protein modeling
The homology model of promyostatin was generated with
the automated protein structure homology-modeling server
SWISS-MODEL Version 8.05 (http://swissmodel.expasy.
org) as described previously [11].
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